Zhou Rong-Rong, Kuang Xu-Yuan, Huang Yan, Li Ning, Zou Ming-Xiang, Tang Dao-Lin, Fan Xue-Gong
a Department of infectious diseases and Key laboratory of liver hepatitis in Hunan ; Xiangya Hospital ; Central South University ; Changsha , PR China.
Cell Adh Migr. 2014;8(5):493-8. doi: 10.4161/19336918.2014.969139.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is characterized as a typical inflammation-related carcinoma. High mobility group box protein 1 (HMGB1), a non-histone DNA-binding protein, is identified as a potent proinflammatory mediator when presents extracellularly. Recently, a growing body of evidence indicates that HMGB1 plays a potential role in HCC, but many questions remain unanswered about the relationship between HMGB1 and HCC formation and development. This review focuses on the biological effect of HMGB1, and discusses the association of HMGB1 with HCC and potential use of strategies targeting HMGB1 in HCC treatment.
肝细胞癌(HCC)是全球最常见的癌症之一,是典型的炎症相关癌。高迁移率族蛋白B1(HMGB1)是一种非组蛋白DNA结合蛋白,在细胞外存在时被鉴定为一种强效促炎介质。最近,越来越多的证据表明HMGB1在HCC中发挥潜在作用,但关于HMGB1与HCC发生发展之间的关系仍有许多问题未得到解答。本综述重点关注HMGB1的生物学效应,并讨论HMGB1与HCC的关联以及靶向HMGB1的策略在HCC治疗中的潜在应用。